Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations

Thrombosis and Haemostasis

Volumn 99, Issue 3, 2008, Pages 616-622

  Tiede, Andreas ^a   Tait, R Campbell ^b   Shaffer, Don W ^c   Baudo, Francesco ^d   Boneu, Bernard ^e   Dempfle, Carl Erik ^f   Horellou, Marie Helene ^g   Klamroth, Robert ^h   Lazarchick, John ⁱ   Mumford, Andrew D ^j   Schulman, Sam ^k   Shiach, Caroline ^l   Bonfiglio, Laura J ^m   Frieling, Johan T M ^m   Conard, Jacqueline ^g   Von Depka, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c WellStar Health Systems   (United States)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e CHU RANGUEIL   (France)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g HÔTEL DIEU   (France)

^h VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^m GTC Biotherapeutics Inc   (United States)

more..

Author keywords

Antithrombin alfa; ATryn ; Deep vein thrombosis; Hereditary antithrombin deficiency; Recombinant human antithrombin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ANTITHROMBIN ALFA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY PRODUCTION; ANTITHROMBIN DEFICIENCY; ARTICLE; CESAREAN SECTION; CHILDBIRTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ELECTIVE SURGERY; FEMALE; GENETIC DISORDER; HIGH RISK POPULATION; HUMAN; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; SURGICAL PATIENT; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBINS; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS, INHERITED; CESAREAN SECTION; DELIVERY, OBSTETRIC; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAMMAPLASTY; MIDDLE AGED; PHLEBOGRAPHY; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; UNITED STATES; VENOUS THROMBOSIS;

EID: 42249086482     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-08-0489     Document Type: Article

References (19)

1. Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 94-100.
2. Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 2005; 3: 1603-1610.
3. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
4. Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38: 481-498.
5. Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-4571.
6. Antithrombin alfa (Atryn) Investigator's Brochure.
7. Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43: 390-394.
8. Knight R, Stanley S, Wong M, et al. Hemophilia therapy and blood-borne pathogen risk. Semin Thromb Hemost 2006; 32 (Suppl 2): 3-9.
9. Turner ML. Prion reduction filters. Lancet 2006; 368: 2190-2191.
10. Final Study Report: A single-dose pharmacokinetic study of recombinant human antithrombin (rhAT) III in patients with hereditary AT III deficiency. Data on file: GTC Biotherapeutics, Inc., MA, USA, 2003.
11. Menache D. Replacement therapy in patients with hereditary antithrombin III deficiency. Semin Hematol 1991; 28: 31-38.
12. Brandt P. Observations during the treatment of antithrombin-III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion. Thromb Res 1981; 22: 15-24.
13. Menache D, O'Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 1990; 75: 33-39.
14. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-141.
15. Brandt P, Stenbjerg S. Subcutaneous heparin for thrombosis in pregnant women with hereditary antithrombin deficiency. Lancet 1979; 1: 100-101.
16. Elias A, Cadene A, Elias M, et al. Extended lower limb venous ultrasound for the diagnosis of proximal and distal vein thrombosis in asymptomatic patients after total hip replacement. Eur J Vasc Endovasc Surg 2004; 27: 438-444.
17. Robertson L, Greer I. Thromboembolism in pregnancy. Curr Opin Obstet Gynecol 2005; 17: 113-116.
18. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742-748.
19. McColl MD, Ramsay JE, Tait RC et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-1188.